Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate efficacy and safety of 3 doses of BIIL 284 BS in active rheumatoid arthritis
(RA) and determine the dose with most positive efficacy / safety ratio. Pharmacokinetic
profile will be also obtained.